SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

Genotropin

PFE·PFIZER INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 1995.
Why 3/10
Genotropin is an already-approved, marketed drug with no pending regulatory decision or pivotal readout scheduled in the next 12 months. It is a small, declining product within Pfizer's massive $63B+ portfolio and not among the top 10 revenue drivers. The defining binary catalysts (initial FDA approval, label expansions) are long past. Impact score is 3 per the rubric: an approved drug with no upcoming binary catalyst.
Actionable Insight NEUTRAL

There are no near-term binary catalysts for Genotropin. Watch for updates on the reusable pen device shortage (expected to last until at least early 2027) and for continued erosion of market share to biosimilar Omnitrope and Pfizer's own once-weekly NGENLA. For Pfizer investors, the drug is a minor, declining contributor within a $63B+ portfolio.

Price Chart

Loading chart...

Executive Summary

Genotropin (somatropin) is Pfizer's recombinant human growth hormone, FDA-approved since the 1990s for multiple pediatric and adult growth disorders. It is a mature, off-patent product facing biosimilar competition (Sandoz's Omnitrope) and internal cannibalization from Pfizer's own once-weekly long-acting growth hormone NGENLA (somatrogon). Genotropin is not among Pfizer's top 10 revenue drivers and represents a very small portion of Pfizer's $63 billion annual revenue. The drug has no upcoming binary catalysts, and its reusable pen device has been in shortage since early 2026. For a Pfizer investor, Genotropin is a legacy product in slow decline, not a needle-moving asset.

How It Works

Genotropin is a synthetic (recombinant) version of human growth hormone, the natural hormone produced by the pituitary gland that stimulates growth in children and helps maintain normal body composition in adults. It is injected under the skin and works by binding to growth hormone receptors throughout the body, stimulating the production of insulin-like growth factor 1 (IGF-1), which promotes bone and muscle growth.

Trial Status

Genotropin has been FDA-approved since 1995 and is a commercially marketed product. The original NDA (020280) has been supplemented multiple times to add indications including pediatric growth hormone deficiency, Prader-Willi syndrome, Small for Gestational Age, Turner syndrome, Idiopathic Short Stature, and adult growth hormone deficiency. No new pivotal trials are ongoing for this molecule; Pfizer's growth hormone focus has shifted to its once-weekly product NGENLA (somatrogon).

The Two-Sided Case

▲ Bull Case3
Genotropin remains a trusted, established brand with multiple FDA-approved indications across pediatric and adult growth disorders, providing a stable base of recurring prescriptions.
Pfizer has transitioned to a next-generation product (NGENLA, once-weekly somatrogon) that extends its franchise in the growth hormone market, potentially capturing patients who prefer fewer injections.
The global somatropin market is valued at roughly $4.3-$4.8 billion in 2026 and is projected to grow at 5.9-7.5% CAGR through the mid-2030s, providing a rising tide that benefits all players.
▼ Bear Case4
Genotropin is well past patent exclusivity and faces direct biosimilar competition from Sandoz's Omnitrope (approved since 2006), which has already driven down pricing in the category.
The reusable pen device for Genotropin has been out of stock since early 2026, with shortages expected until at least early 2027, disrupting patient access and potentially driving switching to competitors.
Pfizer's own once-weekly NGENLA (somatrogon) is cannibalizing Genotropin's daily-injection franchise, and Genotropin is not among Pfizer's top 10 products by revenue, making it a minor contributor to the company's $63B+ annual revenue.
Multiple competitors including Novo Nordisk (Norditropin), Sandoz (Omnitrope), and others compete in the somatropin market, limiting pricing power.

Upcoming Catalysts

  • No upcoming regulatory catalysts for Genotropin specifically. The reusable pen device shortage is expected to last until at least early 2027. Pfizer's growth hormone strategy has shifted to NGENLA (once-weekly somatrogon).

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 10

Hover a chip for the title
1 pfizer.com2 pfizermedical.com3 pituitary.org.uk4 drugpatentwatch.com5 pfizer.com6 stocklight.com7 sec.gov8 accessdata.fda.gov9 ashp.org10 genotropin.com